personalized medicine

Latest Headlines

Latest Headlines

Imaging, informatics steer cancer regimen

Tissue-based biomarker technology that can simultaneously map more than 25 proteins in tumors at the sub-cellular level is the product of a two-year-old collaboration between GE Global Research

Sequencing looms as a game changer

Yesterday I was excited to see a feature story in the San Jose Mercury News reporting that Complete Genomics had cut the price point on full genome sequencing from $250,000 to $4,000. That's a little

Metabolic profiling offers new approach to personalized medicine

Metabolic profiling--an analysis of chemical reactions in the body--holds the promise of selecting the best drug at an optimum dose for a patient, according to a group of scientists in the U.K.

Grant supports personalized medicine tools

Systems biology company GeneGo has been awarded a small business research grant by the National Institutes of Health to develop a database and systems biology tool-set to study mutations and sequence

Personalized cancer vax improves survival rates

A personalized cancer vaccine derived by mixing a patient's dendritic immune cells with an immune stimulator significantly improved the survival rates of a group of people afflicted by metastatic

DNA barcoding for genetic research

Aurora Health Care is launching an IT-fueled research effort to support personalized medicine based on genetic research. The Orbit program creates a repository of lab specimens and electronic health

Scientist blueprints $245M research institute

Dietrich Stephan was a founding scientist at the $90 million Translational Genomics Research Institute in Phoenix. Now he has ambitious plans to establish a $245 million research institute in

Genzyme lines up $600M for personalized meds

Genzyme CEO Henri Termeer (photo) said yesterday that his company--the world's largest developer of rare disease treatments--will spend about $600 million in 2009 to acquire new products for chronic

Personalized medicine comes into its own

Last November I hosted a webinar on the personalized medicine trend. It drove home one more time how an explosion of new genetics research is highlighting the mechanisms that dictate an individual's

FDA advisers skeptical of retrospective genetic analysis

An FDA advisory committee took a dim view of two prominent developers' attempt to use a retrospective look at drug data to make a case that cancer drugs should be reserved for a specific population